{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:32:45Z","timestamp":1794058365002,"version":"4.8.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01114-5","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:03:29Z","timestamp":1771409009000},"page":"435-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7836-4379","authenticated-orcid":false,"given":"Noah F.","family":"Greenwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7608-6515","authenticated-orcid":false,"given":"Iris","family":"Nederlof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Sowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9236-5853","authenticated-orcid":false,"given":"Seongyeol","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-2099","authenticated-orcid":false,"given":"Kathleen E.","family":"Houlahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5757-6818","authenticated-orcid":false,"given":"Sricharan Reddy","family":"Varra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-0565","authenticated-orcid":false,"given":"Jolene S.","family":"Ranek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Voorwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"de Maaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"McCaffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6459-6224","authenticated-orcid":false,"given":"Aziz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4217-8555","authenticated-orcid":false,"given":"Christine Yiwen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4924-591X","authenticated-orcid":false,"given":"Christine Camacho","family":"Fullaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zumana","family":"Khair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7255-2766","authenticated-orcid":false,"given":"Brennan G.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeesha","family":"Piyadasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Risom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-3165","authenticated-orcid":false,"given":"Alea","family":"Delmastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-2276","authenticated-orcid":false,"given":"Felix J.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-0950","authenticated-orcid":false,"given":"Lise","family":"Mangiante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8228-477X","authenticated-orcid":false,"given":"Cristina","family":"Sotomayor-Vivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1341-2453","authenticated-orcid":false,"given":"Sean C.","family":"Bendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0517-8804","authenticated-orcid":false,"given":"Ton N.","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4912-8059","authenticated-orcid":false,"given":"Marc","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"van de Vijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tibshirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4782-8828","authenticated-orcid":false,"given":"Hugo M.","family":"Horlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-3802","authenticated-orcid":false,"given":"Christina","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-9815","authenticated-orcid":false,"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-5067","authenticated-orcid":false,"given":"Michael","family":"Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"1114_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1114_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1114_CR3","doi-asserted-by":"crossref","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976\u20131986; erratum 379, 2185 (2018).","DOI":"10.1056\/NEJMc1808251"},{"key":"1114_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","volume":"30","author":"YL Verschoor","year":"2024","unstructured":"Verschoor, Y. L. et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial. Nat. Med. 30, 519\u2013530 (2024).","journal-title":"Nat. Med."},{"key":"1114_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N. Engl. J. Med. 386, 556\u2013567 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1114_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396, 1090\u20131100 (2020).","journal-title":"Lancet"},{"key":"1114_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens, L. A. et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 5, 74\u201382 (2019).","journal-title":"JAMA Oncol."},{"key":"1114_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1114_CR9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"1114_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J. Natl Cancer Inst. 113, 1005\u20131016 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"1114_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl, S. et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol. 30, 1279\u20131288 (2019).","journal-title":"Ann. Oncol."},{"key":"1114_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41591-020-01189-2","volume":"27","author":"T Bachelot","year":"2021","unstructured":"Bachelot, T. et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat. Med. 27, 250\u2013255 (2021).","journal-title":"Nat. Med."},{"key":"1114_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00317","volume":"7","author":"S Loi","year":"2023","unstructured":"Loi, S. et al. Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 exploratory analysis. JCO Precis. Oncol. 7, e2200317 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"1114_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920\u2013928 (2019).","journal-title":"Nat. Med."},{"key":"1114_CR15","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","volume":"30","author":"I Nederlof","year":"2024","unstructured":"Nederlof, I. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat. Med. 30, 3223\u20133235 (2024).","journal-title":"Nat. Med."},{"key":"1114_CR16","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","volume":"621","author":"XQ Wang","year":"2023","unstructured":"Wang, X. Q. et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature 621, 868\u2013876 (2023).","journal-title":"Nature"},{"key":"1114_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","volume":"41","author":"O Elhanani","year":"2023","unstructured":"Elhanani, O., Ben-Uri, R. & Keren, L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell 41, 404\u2013420 (2023).","journal-title":"Cancer Cell"},{"key":"1114_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41586-019-1876-x","volume":"578","author":"HW Jackson","year":"2020","unstructured":"Jackson, H. W. et al. The single-cell pathology landscape of breast cancer. Nature 578, 615\u2013620 (2020).","journal-title":"Nature"},{"key":"1114_CR19","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren, L. et al. A structured tumor\u2013immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell 174, 1373\u20131387.e19 (2018).","journal-title":"Cell"},{"key":"1114_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","volume":"41","author":"OS Blomberg","year":"2023","unstructured":"Blomberg, O. S. et al. IL-5-producing CD4 T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell 41, 106\u2013123.e10 (2023).","journal-title":"Cancer Cell"},{"key":"1114_CR21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nm.3488","volume":"20","author":"M Angelo","year":"2014","unstructured":"Angelo, M. et al. Multiplexed ion beam imaging of human breast tumors. Nat. Med. 20, 436\u2013442 (2014).","journal-title":"Nat. Med."},{"key":"1114_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41587-021-01094-0","volume":"40","author":"NF Greenwald","year":"2022","unstructured":"Greenwald, N. F. et al. Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning. Nat. Biotechnol. 40, 555\u2013565 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1114_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40068-5","volume":"14","author":"CC Liu","year":"2023","unstructured":"Liu, C. C. et al. Robust phenotyping of highly multiplexed tissue imaging data using pixel-level clustering. Nat. Commun. 14, 4618 (2023).","journal-title":"Nat. Commun."},{"key":"1114_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","volume":"2","author":"IP da Silva","year":"2014","unstructured":"da Silva, I. P. et al. Reversal of NK-cell exhaustion in advanced melanoma by TIM-3 blockade. Cancer Immunol. Res. 2, 410\u2013422 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"1114_CR25","doi-asserted-by":"publisher","first-page":"eaah4323","DOI":"10.1126\/scisignal.aah4323","volume":"10","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. TIM-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss. Sci. Signal. 10, eaah4323 (2017).","journal-title":"Sci. Signal."},{"key":"1114_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25758-2","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Sequential actions of EOMES and T-bet promote stepwise maturation of natural killer cells. Nat. Commun. 12, 5446 (2021).","journal-title":"Nat. Commun."},{"key":"1114_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa, A. et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463\u2013479.e10 (2018).","journal-title":"Cancer Cell"},{"key":"1114_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42479-w","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial. Nat. Commun. 14, 6654 (2023).","journal-title":"Nat. Commun."},{"key":"1114_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1114_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","volume":"24","author":"P Savas","year":"2018","unstructured":"Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986\u2013993 (2018).","journal-title":"Nat. Med."},{"key":"1114_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1114_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1114_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s43018-020-0026-6","volume":"1","author":"HR Ali","year":"2020","unstructured":"Ali, H. R. et al. Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nat. Cancer 1, 163\u2013175 (2020).","journal-title":"Nat. Cancer"},{"key":"1114_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the Lasso. J. R. Stat. Soc. B 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc. B"},{"key":"1114_CR35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s43018-021-00190-z","volume":"2","author":"KL McNamara","year":"2021","unstructured":"McNamara, K. L. et al. Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nat. Cancer 2, 400\u2013413 (2021).","journal-title":"Nat. Cancer"},{"key":"1114_CR36","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen, L. et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade. Cancer Discov. 8, 1156\u20131175 (2018).","journal-title":"Cancer Discov."},{"key":"1114_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"1114_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"1114_CR39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274\u2013278 (2020).","journal-title":"Nature"},{"key":"1114_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. Nat. Rev. Cancer 23, 295\u2013316 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"1114_CR41","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","volume":"185","author":"AM Luoma","year":"2022","unstructured":"Luoma, A. M. et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell 185, 2918\u20132935.e29 (2022).","journal-title":"Cell"},{"key":"1114_CR42","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"1114_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","volume":"42","author":"SL Shiao","year":"2024","unstructured":"Shiao, S. L. et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell 42, 70\u201384.e8 (2024).","journal-title":"Cancer Cell"},{"key":"1114_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40\u201350 (2018).","journal-title":"Lancet Oncol."},{"key":"1114_CR45","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jamaoncol.2024.1917","volume":"10","author":"VCM Geurts","year":"2024","unstructured":"Geurts, V. C. M. et al. Tumor-infiltrating lymphocytes in patients with stage I triple-negative breast cancer untreated with chemotherapy. JAMA Oncol. 10, 1077\u20131086 (2024).","journal-title":"JAMA Oncol."},{"key":"1114_CR46","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi, S. et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J. Clin. Oncol. 37, 559\u2013569 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1114_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91\u2013113 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1114_CR48","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"F-C Bidard","year":"2022","unstructured":"Bidard, F.-C. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 23, 1367\u20131377 (2022).","journal-title":"Lancet Oncol."},{"key":"1114_CR49","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","volume":"27","author":"A Bassez","year":"2021","unstructured":"Bassez, A. et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 27, 820\u2013832 (2021).","journal-title":"Nat. Med."},{"key":"1114_CR50","doi-asserted-by":"publisher","first-page":"101495","DOI":"10.1016\/j.esmoop.2023.101495","volume":"8","author":"JM Ribeiro","year":"2023","unstructured":"Ribeiro, J. M. et al. 156TiP Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program). ESMO Open 8, 101495 (2023).","journal-title":"ESMO Open"},{"key":"1114_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1\u201310 (1989).","journal-title":"Control. Clin. Trials"},{"key":"1114_CR52","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1158\/0008-5472.CAN-20-1792","volume":"80","author":"M Huang","year":"2020","unstructured":"Huang, M. et al. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis. Cancer Res. 80, 5427\u20135434 (2020).","journal-title":"Cancer Res."},{"key":"1114_CR53","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164\u2013172 (2014).","journal-title":"Lancet"},{"key":"1114_CR54","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur. J. Cancer 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"},{"key":"1114_CR55","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"key":"1114_CR56","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cell.2021.12.023","volume":"185","author":"T Risom","year":"2022","unstructured":"Risom, T. et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell 185, 299\u2013310.e18 (2022).","journal-title":"Cell"},{"key":"1114_CR57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41590-021-01121-x","volume":"23","author":"EF McCaffrey","year":"2022","unstructured":"McCaffrey, E. F. et al. The immunoregulatory landscape of human tuberculosis granulomas. Nat. Immunol. 23, 318\u2013329 (2022).","journal-title":"Nat. Immunol."},{"key":"1114_CR58","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41374-022-00778-8","volume":"102","author":"CC Liu","year":"2022","unstructured":"Liu, C. C. et al. Reproducible, high-dimensional imaging in archival human tissue by multiplexed ion beam imaging by time-of-flight (MIBI-TOF). Lab. Invest. 102, 762\u2013770 (2022).","journal-title":"Lab. Invest."},{"key":"1114_CR59","doi-asserted-by":"publisher","unstructured":"Bosse, M. et al. MIBI and IHC solutions. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.bhmej43e (2021).","DOI":"10.17504\/protocols.io.bhmej43e"},{"key":"1114_CR60","doi-asserted-by":"publisher","unstructured":"Bosse, M. IHC staining V.1. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.bf6ajrae (2021).","DOI":"10.17504\/protocols.io.bf6ajrae"},{"key":"1114_CR61","doi-asserted-by":"publisher","unstructured":"Bosse, M. et al. MIBI staining V.5. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.dm6gprk2dvzp\/v5 (2022).","DOI":"10.17504\/protocols.io.dm6gprk2dvzp\/v5"},{"key":"1114_CR62","doi-asserted-by":"publisher","unstructured":"Bosse, M. et al. Staining sequenza. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.bmc6k2ze (2021).","DOI":"10.17504\/protocols.io.bmc6k2ze"},{"key":"1114_CR63","doi-asserted-by":"publisher","unstructured":"Camacho, C. et al. Antibody lyophilization. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.bhmgj43w (2021).","DOI":"10.17504\/protocols.io.bhmgj43w"},{"key":"1114_CR64","doi-asserted-by":"publisher","unstructured":"Greenwald, N. et al. Greenwald, Nederlof et al extended methods V.2. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.e6nvw44k7lmk\/v2 (2025).","DOI":"10.17504\/protocols.io.e6nvw44k7lmk\/v2"},{"key":"1114_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-020-03879-7","volume":"21","author":"JS Medina-Mart\u00ednez","year":"2020","unstructured":"Medina-Mart\u00ednez, J. S. et al. Isabl Platform, a digital biobank for processing multimodal patient data. BMC Bioinformatics 21, 549 (2020).","journal-title":"BMC Bioinformatics"},{"key":"1114_CR66","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"1114_CR67","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/bioinformatics\/btv566","volume":"32","author":"K Okonechnikov","year":"2016","unstructured":"Okonechnikov, K., Conesa, A. & Garc\u00eda-Alcalde, F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics 32, 292\u2013294 (2016).","journal-title":"Bioinformatics"},{"key":"1114_CR68","doi-asserted-by":"publisher","unstructured":"Benjamin, D. et al. Calling somatic SNVs and indels with Mutect2. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/861054 (2019).","DOI":"10.1101\/861054"},{"key":"1114_CR69","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"1114_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"1114_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1114_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0431-1","volume":"15","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol. 15, 431 (2014).","journal-title":"Genome Biol."},{"key":"1114_CR73","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 30, 3310\u20133316 (2014).","journal-title":"Bioinformatics"},{"key":"1114_CR74","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"1114_CR75","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cels.2019.08.009","volume":"9","author":"LP Richman","year":"2019","unstructured":"Richman, L. P., Vonderheide, R. H. & Rech, A. J. Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade. Cell Syst. 9, 375\u2013382 (2019).","journal-title":"Cell Syst."},{"key":"1114_CR76","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1114_CR77","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e7 (2021).","journal-title":"Cancer Cell"},{"key":"1114_CR78","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395\u2013399 (2012).","journal-title":"Nature"},{"key":"1114_CR79","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750\u20132767 (2011).","journal-title":"J. Clin. Invest."},{"key":"1114_CR80","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/s41588-019-0532-6","volume":"51","author":"J van den Eynden","year":"2019","unstructured":"van den Eynden, J., Jim\u00e9nez-S\u00e1nchez, A., Miller, M. L. & Larsson, E. Lack of detectable neoantigen depletion signals in the untreated cancer genome. Nat. Genet. 51, 1741\u20131748 (2019).","journal-title":"Nat. Genet."},{"key":"1114_CR81","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1093\/bioinformatics\/btac356","volume":"38","author":"Z Fang","year":"2022","unstructured":"Fang, Z. & Peltz, G. An automated multi-modal graph-based pipeline for mouse genetic discovery. Bioinformatics 38, 3385\u20133394 (2022).","journal-title":"Bioinformatics"},{"key":"1114_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35238-w","volume":"14","author":"S Tietscher","year":"2023","unstructured":"Tietscher, S. et al. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat. Commun. 14, 98 (2023).","journal-title":"Nat. Commun."},{"key":"1114_CR83","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.immuni.2012.08.021","volume":"37","author":"TA Doering","year":"2012","unstructured":"Doering, T. A. et al. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 37, 1130\u20131144 (2012).","journal-title":"Immunity"},{"key":"1114_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101511","volume":"5","author":"L Xu","year":"2024","unstructured":"Xu, L. et al. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell Rep. Med. 5, 101511 (2024).","journal-title":"Cell Rep. Med."},{"key":"1114_CR85","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1114_CR86","doi-asserted-by":"publisher","unstructured":"Greenwald, N. et al. Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition. Zenodo https:\/\/doi.org\/10.5281\/zenodo.14112852 (2025).","DOI":"10.5281\/zenodo.14112852"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01114-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:02:52Z","timestamp":1774864972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01114-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":86,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1114"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01114-5","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.F.G. is an advisor for Cellformatica. T.N.S. is advisor for Allogene Therapeutics, Asher Bio, Merus, Neogene Therapeutics and Scenic Biotech, is a stockholder in Allogene Therapeutics, Asher Bio, Cell Control, Celsius, Merus and Scenic Biotech and is venture partner at Third Rock Ventures, all outside of the current work. M.K. reports research funding to the institute from BMS, Roche and AstraZeneca\/MedImmune and an advisory role\/speakers fee (all compensated to the institute) for Alderaan, BMS, Domain Therapeutics, Medscape, Roche, MSD and Daiichi Sankyo, outside the submitted work. M.A. is a named inventor on patent US20150287578A1, which covers the mass spectrometry approach used by MIBI to detect elemental reporters in tissue using secondary-ion mass spectrometry. M.A. is a board member and shareholder in IonPath, which develops and manufactures the commercial MIBI platform. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}